Selvita

Selvita EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Selvita (SLV.WA) as of Oct 22, 2026 is 7.27 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 52.61 M PLN — a change of -86.19% (lower).

EBITDA

7.27 MPLN

YoY

-86.19%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Selvita is 2025 7.27 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Selvita was 2024 52.61 M PLN. It decreases by -86.19% lower compared to the previous year.

The Selvita EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
11.13 M PLN
Jan 1, 2019
6.46 M PLN
Jan 1, 2020
33.07 M PLN
Jan 1, 2021
53.57 M PLN
Jan 1, 2022
75.41 M PLN
Jan 1, 2023
114.76 M PLN
Jan 1, 2024
52.61 M PLN
Jan 1, 2025
7.27 M PLN
The Selvita EBITDA history
YEAREBITDAYoY
7.27 MPLN-86.19%
52.61 MPLN-54.16%
114.76 MPLN+52.20%
75.41 MPLN+40.75%
53.57 MPLN+62.00%
33.07 MPLN+411.53%
6.46 MPLN-41.93%
11.13 MPLN+66.12%
6.70 MPLN-651.98%
-1.21 MPLN-158.56%
2.07 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Selvita Stock analysis

What does Selvita do? Selvita SA generates revenue through multidisciplinary solutions for drug discovery, regulatory studies, and research and development. The company provides early-stage drug discovery support, including target validation and clinical candidate selection, alongside drug testing and bioanalytical services such as method development, stability studies, and quality control testing. Its clients include pharmaceutical companies and research institutions across Europe and the United States, which rely on Selvita's expertise for comprehensive project support throughout the drug development lifecycle. The firm's services span the entire drug discovery process, from initial target identification to preclinical research and clinical candidate selection. By offering end-to-end solutions, Selvita caters to clients seeking efficient and reliable support in complex research phases. Its collaborations with European and American research institutes and universities further strengthen its position in the biotech and pharmaceutical sectors. Selvita SA's business model focuses on delivering specialized scientific services tailored to the needs of clients in drug development. The company's offerings cover all critical stages of the drug discovery process, ensuring clients can advance their projects with minimal delays. This approach allows Selvita to maintain strong relationships with its key clients in the pharmaceutical and research communities. Selvita is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Selvita stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Selvita is 7.27 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Selvita changed from 52.61 M PLN to 7.27 M PLN, representing a -86.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Selvita since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Selvita historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Selvita

All Key Metrics — Selvita